CombiPatch

What it is

CombiPatch is a brand-name twice-weekly transdermal patch that combines two hormones in a single patch: 17β-estradiol (bioidentical estrogen) plus norethindrone acetate, a synthetic progestin. It is FDA-approved for moderate-to-severe vasomotor symptoms of menopause and moderate-to-severe symptoms of vulvar and vaginal atrophy in women with a uterus.

CombiPatch is available in two strengths: 0.05 mg estradiol / 0.14 mg norethindrone acetate per day, and 0.05 mg estradiol / 0.25 mg norethindrone acetate per day. Both CombiPatch doses deliver the same amount of estrogen — the difference is the amount of progestin, and clinicians usually pick based on bleeding pattern and tolerability.

The patch is a small, translucent oval worn on the lower abdomen and changed twice a week (every 3–4 days). It can also be used as add-back therapy in women with a uterus who are already using an estradiol patch (Climara, Vivelle-Dot, Alora, Minivelle) — CombiPatch replaces the estrogen patch for the second half of a sequential regimen.

Because CombiPatch contains both estrogen and progestin in one patch, it eliminates the need for a separate nightly progesterone pill. This is the main reason patients pick CombiPatch over an estradiol patch plus oral micronized progesterone (Prometrium).

How it works

The CombiPatch delivers estradiol and norethindrone acetate continuously through the skin, bypassing the liver "first-pass" that occurs with oral hormones. Transdermal delivery is preferred by NAMS 2022 and the Endocrine Society for patients with elevated VTE risk, migraine with aura, high triglycerides, or gallbladder disease.

The estradiol component stabilizes the hypothalamic thermoregulatory center, which is what reduces hot flashes and night sweats — typically by 75–80% within 8–12 weeks. It also restores vaginal tissue, supports bone mineral density, and stabilizes sleep for many patients.

The norethindrone acetate component provides endometrial protection. Estrogen alone in a woman with a uterus increases the risk of endometrial hyperplasia and endometrial cancer; adding a progestogen suppresses that risk. CombiPatch registration trials demonstrated endometrial safety at both doses over 12 months of continuous use.

Who it's for

• Postmenopausal women with a uterus who have moderate-to-severe hot flashes, night sweats, or genitourinary symptoms
• Women who want a single combined patch instead of managing an estradiol patch plus a nightly progesterone pill
• Patients with elevated cardiovascular or thrombotic risk where transdermal is preferred over oral combined HRT
• Women who tolerated norethindrone-based oral contraceptives well in the past
• Women using an estradiol patch cyclically who need a sequential 12–14 day progestin phase each month

Who should not take it

• Personal history of breast cancer or other estrogen-sensitive cancer
• Active or recent blood clot, stroke, transient ischemic attack, or heart attack
• Active liver disease
• Undiagnosed abnormal vaginal bleeding
• Known or suspected pregnancy
• Women who have had a hysterectomy (estrogen alone — a plain estradiol patch — is appropriate; the progestin in CombiPatch is unnecessary)
• Known hypersensitivity to any patch component

Common side effects

• Skin irritation, redness, or itching at the patch site — the most common CombiPatch side effect. Rotate the application site each patch-change to minimize.
• Breast tenderness, mild bloating, or headache during the first 4–6 weeks — usually resolves as the dose stabilizes.
• Spotting or breakthrough bleeding, especially during the first 3–6 months. This is the single most common reason patients switch between the 0.14 and 0.25 mg doses of CombiPatch.
• Mood changes — a minority of patients are sensitive to synthetic progestins (norethindrone acetate) and feel flat, low, or anxious. If this occurs, switching to an estradiol patch plus bioidentical micronized progesterone (Prometrium) is usually the next step.
• Nausea (less common than with oral combined HRT because CombiPatch bypasses the liver).
• Occasional patch-adhesion issues with heavy sweating or prolonged hot-tub use.

Evidence summary

• FDA-approved indications: moderate-to-severe vasomotor symptoms of menopause and moderate-to-severe symptoms of vulvar and vaginal atrophy in postmenopausal women with a uterus.
• CombiPatch registration trials: ~80% reduction in weekly hot flash frequency by week 12 versus placebo; endometrial hyperplasia rates equivalent to combined oral HRT over 12 months.
• NAMS 2022 Hormone Therapy Position Statement: micronized progesterone is the preferred progestogen when available, but norethindrone acetate (as in CombiPatch) is an acceptable alternative, particularly when a single-patch delivery is clinically preferred.
• Transdermal combined HRT is associated with a lower VTE risk than oral combined HRT in observational data (E3N cohort, French national cohort studies).

Brand-name vs compounded

CombiPatch is an FDA-approved brand-name product. Many Kindr patients use compounded alternatives prepared by a state-licensed 503A pharmacy when a custom dose, custom combination, or different delivery form is clinically preferable. Both pathways are available through Kindr — your provider will recommend based on your individual needs.

FAQ

Sources

• NAMS 2022 Hormone Therapy Position Statement
• ACOG: Menopausal Symptom Management
• U.S. Food & Drug Administration
• CombiPatch FDA prescribing information
• Endocrine Society Menopause Guideline

Other medications

This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.